Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Pre-Tax Margin

Income before tax as a percentage of revenue.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -1207650.0%

Pre-tax margin was -1207650.0% in Q1 FY2026, down 462007.1 pp from a year earlier. On a trailing-twelve-month basis it was -794858.1%, down 280208.8 pp year over year. Over 3 fiscal years it narrowed by 762139.3 pp.

Context

  • Pre-tax margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-1207650.0%+1137733.3 pp QoQ
Last fiscal yearDec 2025
-762355.6%-200070.3 pp YoY
LTMMar 2026
-794858.1%-280208.8 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-462007.1 pp——
1 year-200070.3 pp——
3 years-762139.3 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-762355.6%
Year-over-year change
-200070.3pp

Pre-Tax Margin vs competitors

How LYEL compares with its peers on the latest reported figures

  • LYEL's LTM Mar 2026 pre-tax margin of -794858.1% is the lowest of the 6 companies compared; the peer median is -1788.8%.
  • Its year-over-year change of -280208.8 pp is the lowest of 4, against a peer median of +22.2 pp.
  • Over three fiscal years its change of -762139.3 pp compares with a peer median of -173.9 pp.
LYEL Competitors Peer median
Pre-Tax Margin for LYEL and competitors
Company Period LTM level YoY 3-year change
AMRNAmarin Corporation plcLTM Mar 2026-16.2% +22.2 pp+11.2 pp
EDITEditas Medicine, Inc.LTM Mar 2026-281.6% +419.5 pp+723.2 pp
ACIUAC Immune S.A.LTM Mar 2026-1788.8% -1604.8 pp-173.9 pp
SLNSilence Therapeutics plcLTM Mar 2026-9241.5% —-15620.7 pp
GNLXGenelux CorporationLTM Mar 2026-397225.0% —-401775.4 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-794858.1% -280208.8 pp-762139.3 pp
LRMRLarimar Therapeutics, Inc.FY2025— ——
KYTXKyverna Therapeutics, Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding LYEL) -1788.8%+22.2 pp-173.9 pp

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.